Approaches to the pharmacotherapy of diabetic macular edema: Literature review

Cover Page

Cite item

Full Text

Abstract

  • Pharmacotherapy of diabetic retinopathy and diabetic macular edema can be subdivided into groups according to the class of drugs, the most important of which are vascular endothelial growth factor inhibitors and corticosteroids. Intravitreal administration of these drugs is more preferable. The systemic use of angiotensin and fibrate receptor blockers is of least importance. The use of eye drops of non-steroidal anti-inflammatory drugs does not have convincing evidence of the efficacy in the treatment of diabetic macular edema. The article presents the results of the main studies on the development of algorithms for the treatment of diabetic retinopathy and diabetic macular edema.

About the authors

Irina V. Ionkina

Sverdlovsk Regional Clinical Hospital No. 1

Author for correspondence.
Email: ionkina_iv@mail.ru

Candidate of Medical Science, ophthalmologist

Russian Federation, Yekaterinburg

Andrey G. Grinev

Sverdlovsk Regional Clinical Hospital No. 1

Email: eyegrin@mail.ru

Dоctor of Medical Science, Head of the 1st Ophthalmological Department

Russian Federation, Yekaterinburg

Olga M. Zherebtsova

Sverdlovsk Regional Clinical Hospital No. 1

Email: zherebtcovaom@mail.ru

ophthalmologist of the 1st Ophthalmological Department

Russian Federation, Yekaterinburg

References

  1. Standards of specialized diabetes care. Ed. by I.I. Dedov, M.V. SHestakov, A.Yu. Majorov. 8th edition. Diabetes Mellitus. 2017;20(1S):1–121. (In Russ.) doi: 10.14341/DM20171S8
  2. Ohocimskaya TD, Zaitseva OV. Aflibercept for the therapy of retinal diseases. A review of clinical studies. Russian ophthalmological journal. 2017;10(2):103–119. (In Russ.)
  3. Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in Russian federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the federal diabetes register, status 2017. Diabetes Mellitus. 2018;21(3):144–159. (In Russ.) doi: 10.14341/DM9686
  4. Shadrichev FE, Grigor’eva NN, Rozhdestvenskaya ES. Anti-angiogenic therapy for diabetic macular edema. Ophthalmology Journal. 2018;11(4):51–66. (In Russ.) doi: 10.17816/OV11451-66
  5. Afridi R, Agarwal A, Sadiq MA, et al. Effects of two different doses of ranibizumab on the resolution and recurrence of diabetic macular edema in the ranibizumab for edema of the macula in diabetes (READ-3) study. ARVO;IOVS. 2016.
  6. Aiello LP, Vignati L, Sheetz MJ, et al. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1392 eyes) with diabetic retinopathy in the protein kinase C β inhibitor diabetic retinopathy study and the proteinkinase C β inhibitor-diabetic retinopathy study. Retina. 2011;31(10):2084–2094. DOI: 10.1097/ IAE.0b013e3182111669
  7. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033–1046. doi: 10.2337/dc12-2625
  8. Bakri SJ, Beer PM. Intravitreal triamcinolone injection for diabetic macular edema: a clinical and fluorescein angiographic case series. Can J Ophthalmol. 2004;39(7):755–760. doi: 10.1016/S0008-4182(04) 80069-3
  9. Blinder KJ, Dugel PU, Chen S, et al. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO study report 1). Clin Ophthalmol. 2017;11:393–401. doi: 10.2147/OPTH.S128509
  10. Boyer DS, Yoon YH, Belfort R, Jr, et al. Three-year, randomized, sham-сontrolled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi: 10.1016/j.ophtha.2014.04.024
  11. Cunningham ET, Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112(10):1747–1757. doi: 10.1016/j.ophtha.2005.06.007
  12. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447–1444. doi: 10.1016/j.ophtha.2008.06.015
  13. Do DV, Sepah YJ, Boyer D, et al. Month-6 primary outcomes of the READ-3 study (Ranibizumab for edema of the mAcula in diabetes-protocol 3 with high dose). Eye (Lond). 2015;29(12):1538–1544. doi: 10.1038/eye.2015.142
  14. Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol I study data. Retina. 2019;39(1):88–97. doi: 10.1097/IAE.0000000000002110
  15. Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net protocol T. Curr Opin Ophthalmol. 2017;28(6):636–643. doi: 10.1097/ICU.0000000000000424
  16. Callanan DG, Loewenstein A, Patel SS, et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2017;255(3):463–473. doi: 10.1007/s00417-016-3472-1
  17. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635. doi: 10.1016/j.ophtha.2010.12.028
  18. Cicinelli MV, Cavalleri M, Querques L, et al. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema. Br J Ophthalmol. 2017;101(12):1689–1693. DOI: 10.1136/ bjophthalmol-2017-310242
  19. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartanon prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372(9647):1394–1402. doi: 10.1016/S0140-6736(08)61412-9
  20. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet. 1998;351(9095):28–31. doi: 10.1016/S0140-6736(97)06209-0
  21. Chase HP, Garg SK, Harris S, et al. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol. 1993;25(8):284–289.
  22. Elman MJ, Aiello LP, Beck RW, et al. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077.e1035. doi: 10.1016/j.ophtha.2010.02.031
  23. Elman MJ, Qin H, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119(11):2312–2318. DOI: 10. 1016/j.ophtha.2012.08.022
  24. Elbendary AM, Shahin MM. Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Retina. 2011;31(10):2058–2064. doi: 10.1097/IAE.0b013e31822a042a
  25. Friedman SM, Almukhtar TH, Baker CW, et al. Topical nepafenec in eyes with noncentral diabetic macular edema. Retina. 2015;35(5):944–956. DOI: 10.1097/ IAE.0000000000000403
  26. Fusi-Rubiano W, Mukherjee C, Lane M, et al. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19 mg Fluocinolone Acetonide intravitreal implant (Iluvien) at 2 years. BMC Ophthalmol. 2018;18(1):62. doi: 10.1186/s12886-0180726-1
  27. Gillies MC, Simpson JM, Billson FA, et al. Safety of intravitreal injection of triamcinolone: results of a randomized clinical trial. Arch Ophthalmol. 2004;122(3):336–340. doi: 10.1001/archopht.122.3.336
  28. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113(9):1533–1538. doi: 10.1016/j.ophtha.2006.02.065
  29. Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–2146. doi: 10.1001/jama.2015.15217
  30. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121(1):57–61. doi: 10.1001/archopht.121.1.57
  31. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132(3):425–427. doi: 10.1016/S0002-9394(01)01010-8
  32. Habib MS. ILUVIEN((R)) technology in the treatment of center-involving diabetic macular edema: a review of the literature. Ther Deliv. 2018;9(8):547–556. doi: 10.4155/tde-2018-0006
  33. Haller JA, Bandello F, Belfort R, Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453–2460. doi: 10.1016/j.ophtha.2011.05.014
  34. Helzner J. Clearside study shows durable response in DME. Retin Physician. 2018;15:E2.
  35. Iglicki M, Zur D, Busch C, et al. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-ProDEX Study’. Acta Diabetol. 2018;55(6):541–547. doi: 10.1007/s005 92-018-1117-z
  36. Ip MS, Domalpally A, Hopkins JJ, et al. Longterm effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145–1152. doi: 10.1001/archophthalmol.2012.1043
  37. Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015;122(2):367–374. doi: 10.1016/j.ophtha.2014.08.048
  38. Kaur S, Yangzes S, Singh S, Sachdev N. Efficacy and safety of topical difluprednate in persistent diabetic macular edema. Int Ophthalmol. 2016;36(3):335–340. doi: 10.1007/s10792-015-0121-3
  39. Khan Z, Kuriakose RK, Khan M, et al. Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: meta-analysis and clinical implications. Ophthalmic Surg Lasers Imaging Retina. 2017;48(2):160–166. doi: 10.3928/23258160-20170130-10
  40. Koc I, Kadayifcilar S, Eldem B. Real-world results of intravitreal ranibizumab, bevacizumab, or triamcinolone for diabetic macular edema. Ophthalmologica. 2018;239(2–3):85–93. doi: 10.1159/000481180
  41. Kim SJ, Schoenberger SD, Thorne JE, et al. Topical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American Academy of Ophthalmology. Ophthalmology. 2015;122(11):2159–2168. doi: 10.1016/j.ophtha. 2015.05.014
  42. Kodjikian L, Bellocq D, Mathis T. Pharmacological management of diabetic macular edema in real-life observational studies. Biomed Res Int. 2018:8289253. doi: 10.1155/2018/8289253
  43. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254. doi: 10.1016/j.ophtha.2014.05.006
  44. Krick TW, Bressler NM. Recent clinically relevant highlights from the diabetic retinopathy clinical research network. Curr Opin Ophthalmol. 2018;29(3):199–205. doi: 10.1097/ICU.0000000000000472
  45. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125(3):309–317. doi: 10.1001/archopht.125.3.309
  46. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99(5):753–759. doi: 10.1016/S0161-6420(92)31901-3
  47. Liu L, Wu X, Geng J, et al. IVTA as adjunctive treatment to PRP and MPC for PDR and macular edema: a meta-analysis. PLoS One. 2012;7(9):e44683. doi: 10.1371/journal. pone.0044683
  48. Malcles A, Dot C, Voirin N, et al. Real-life study in diabetic macular edema treated with dexamethasone implant: the reldex study. Retina. 2017;37(4):753–760. doi: 10.1097/IAE.0000000000001234
  49. Maturi RK, Glassman AR, Liu D, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018;136(1):29–38. doi: 10.1001/jamaophthalmol.2017.4914
  50. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361(1):40–51. doi: 10.1056/NEJMoa0808400
  51. Michael J, Elman MD. To treat or not to treat: are we sacrificing treatment outcomes by allowing diabetic retinopathy (DR) to enter the proliferative stage? American Society of Retina Specialists Annual Meeting; 2018. Vancouver, Canada.
  52. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078–1086.e1072. doi: 10.1016/j.ophtha.2010.03.045
  53. Nakano S, Yamamoto T, Kirii E, et al. Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248(6):805–810. doi: 10.1007/s00417-010-1316-y
  54. Pacella F, Romano MR, Turchetti P, et al. An eighteen — month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol. 2016;9(10):1427–1432. doi: 10.18240/ijo.2016.10.10
  55. Pershing S, Enns EA, Matesic B, et al. Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med. 2014;160(1):18–29. doi: 10.7326/M13-0768
  56. Pessoa B, Coelho J, Correia N, et al. Fluocinolone acetonide intravitreal implant 190 mug (ILUVIEN(R)) in vitrectomized versus nonvitrectomized eyes for the treatment of chronic diabetic macular edema. Ophthalmic Res. 2018;59(2):68–75. doi: 10.1159/000484091
  57. Pinna A, Blasetti F, Ricci GD, Boscia F. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. Eur J Ophthalmol. 2017;27(3):326–330. doi: 10.5301/ejo.5000888
  58. Sadiq MA, Hassan M, Soliman MK, et al. Effects of two different doses of ranibizumab on diabetic retinopathy severity and progression in the ranibizumab for edema of the macula in diabetes (READ-3) study. IOVS. 2016:160.
  59. Schirr-Bonnans S, Costa N, Derumeaux-Burel H, et al. Cost of diabetic eye, renal and foot complications: a methodological review. Eur J Health Econ. 2017;18(3):293–312. doi: 10.1007/s10198-016-0773-6
  60. Schwartz SG, Flynn HW, Jr, Aiello LP. Ruboxistaurin mesilate hydrate for diabetic retinopathy. Drugs Today (Barc). 2009;45(4):269–274. doi: 10.1358/dot.2009.045.004.1354195
  61. Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389(10085):2193–2203. doi: 10.1016/S0140-6736(17)31193-5
  62. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138(5):740–743. doi: 10.1016/j.ajo.2004.06.067
  63. Staurenghi G, Ye L, Magee MH, et al. Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study. Ophthalmology. 2015;122(5):990–996. doi: 10.1016/j.ophtha.2014.12.014
  64. Storey PP, Obeid A, Pancholy M, et al. Ocular hypertension after intravitreal injection of 2-mg triamcinolone. Retina. 2020;40(1):66–74. doi: 10.1097/IAE.0000000000002361
  65. Sugimoto M, Ichio A, Mochida D, et al. Multiple effects of intravitreal aflibercept on microvascular regression in eyes with diabetic macular edema. Ophthalmol Retina. 2019;3(12):1067–1075. doi: 10.1016/j.oret.2019.06.005
  66. Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular edema: a network meta-analysis. Cochrane Database Syst Rev. 2018;10(10):CD007419. doi: 10.1002/14651858.CD007419.pub6
  67. Virk SA, Donaghue KC, Wong TY, Craig ME. Interventions for diabetic retinopathy in type 1 diabetes: systematic review and meta-analysis. Am J Ophthalmol. 2015;160(5):1055–1064.e4. doi: 10.1016/j.ajo.2015.07.024
  68. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–1359. doi: 10.1016/j.ophtha.2016. 02.022
  69. Wielders LH, Lambermont VA, Schouten JS, et al. Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta-analysis. Am J Ophthalmol. 2015;160(5):968–981.e933. doi: 10.1016/j.ajo.2015.07.032
  70. Wykoff CC, Chakravarthy U, Campochiaro PA, et al. Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy. Ophthalmology. 2017;124(4):440–449. doi: 10.1016/j.ophtha.2016.11.034
  71. Wykoff CC, Shah C, Dhoot D, et al. Longitudinal retinal perfusion status in eyes with diabetic macular edema receiving intravitreal aflibercept or laser in VISTA study. Ophthalmology. 2019;126(8):1171–1180. doi: 10.1016/j.ophtha.2019.03.040
  72. Wykoff CC. Intravitreal aflibercept for moderately severe to severe nonproliferative diabetic retinopathy (NPDR): the Phase III PANORAMA Study. American Society of Retina Specialists Annual Meeting. 2018. Vancouver, Canada.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Ionkina I.V., Grinev A.G., Zherebtsova O.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».